Karyopharm Therapeutics Inc.

Bye. Good morning. My name is Carolyn, and I will be your conference operator today. At this time, I would like to welcome everyone to Carrier Farm Therapeutics' second quarter 2024 financial results conference call. There will be a question and answer session to follow. Please be advised that this call is being recorded at the company's request. I would now like to turn the call over to Ellen Webb, Senior Vice President, Investor Relations.

Thank you, Carolyn, and thank you all for joining us on today's conference call to discuss Carefarm's second quarter Q2 2024 financial results and recent company progress. We issued a press release this morning detailing our financial results for Q2 2024. This release, along with a slide presentation that we'll reference during our call today, are available on our website. For today's call, as seen on slide two, I'm joined by Richard, Reshma, Sohania, and Mike, who will provide an update on our results for Q2 2024 and recent clinical developments. Before we begin our formal comments, I remind you that various remarks we'll make today constitute forward-looking statements, FLS, for purposes of the safe harbor provisions under the Privacy Security Litigation Reform Act of 1995, as outlined on slide three. Actual results may differ materially from those indicated by these FLS as a result of various important factors, including those discussed in the risk factors section of our most recent Form 10-Q, which is on file with the SEC and in other filings that we may make with the SEC in the future. Any FLS represent our views as of today only. While we may elect to update these FLS at some point in the future, we specifically disclaim any obligation to do so even if our views change. Therefore, you should not rely on this FLS as representing our views as of any later date. I will now turn the call over to Richard. Please turn to slide four.

Good morning. Thank you, Alhan, and thank you all for joining us today for CarioFarm's Q2 2024 earnings call. Turning to slide five, I would like to first focus on our innovation and growth strategy as we work to deliver our next stage of growth by advancing our late stage pipeline while continuing to strengthen our foundation in multiple myeloma. Starting with myelofibrosis, we are more excited than ever regarding Cell and XOR's potential opportunity in this indication. Physician interest in enrolling patients into our phase three study is strong, and the competitive environment continues to evolve favorably for us. Building on our strong clinical data, The new preclinical data that we presented at EHA further reinforces the role that Selenexor might play in myelofibrosis. In endometrial cancer, we presented updated data at ASCO demonstrating nearly 40 months of progression-free survival when Selenexor is used as a maintenance therapy in patients whose tumors are TP53 wild-type PMMR. This population represents approximately half of all patients who are diagnosed with endometrial cancer. It is noteworthy that the progression-free survival that Celinexor is demonstrating in the maintenance setting in this subgroup exceeds the overall survival that is achieved by the checkpoint inhibitors in patients whose tumors are PMMR. As we continue to enroll patients in our EC042 phase three trial on endometrial cancer, We are also confronting the complexities of a molecularly targeted maintenance trial and are taking proactive actions, both of which Raishma will expand on. As a result, we now expect to deliver top-line data in early 2026. In multiple myeloma, we are pleased to report our second consecutive quarter of growth in Exposio revenue, giving us confidence to raise the low end of our revenue guidance for 2024. The importance of Expovio's differentiated mechanism of action, its all-oral administration, and potentially T-cell sparing impact is increasingly resonating with community and academic physicians, which Sohanya will expand on. As we work to build on our commercial foundation of multiple myeloma, we expect to leverage our positively evolving SPD data at the 40 milligram dose, to update the design of the Phase III EMN29 trial, which will include targeting fewer participants for enrollment and lowering the projected cost of this trial. Finally, in light of our strengthening commercial performance, disciplined cost management, and focused approach to clinical development, we believe we're in a strong financial position to deliver on our prioritized late-stage pipeline. Mike will expand on our lowered 2024 R&D and SG&A expense guidance. We continue to be very optimistic about our next stage of growth and are well positioned to capitalize on the opportunities for Cell and XOR with our diversely built late stage pipeline across three different cancer indications. We continue to believe the annual peak revenue opportunity for Cell and XOR could be $2 billion in the U.S. alone. I would now like to turn the call over to Raishma to expand on our recent data announcements and discuss our progress with each of the programs in our pipeline. Raishma?